Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by PLITheOneon Aug 17, 2021 5:36pm
91 Views
Post# 33721098

RE:DISCLOSING OF UNNEW $ OBLIGATION

RE:DISCLOSING OF UNNEW $ OBLIGATION

wow, Liminal really took it up the wazoo on this deal! Think that those overpaid goons will pay me to take the rest of their assets from them?
Something real fishy about this deal!

The paid Kedrion a lot of money to help steal this technology out the back door!


4Justice wrote: From MD&A

It's not important. We're just talking of $9M a year obligation...!!!

 With the sale of the plasma collection centers during the second quarter of 2021 and the sale of PBP on July 9, 2021, there will be limited cash outflows relating to operational expenses of the plasma-derived therapeutic business with the exception of the continuing obligation we have towards a CDMO organisation but which is no longer required as a result of the PBP sale transaction. The total commitment under this contract is $9.0 million per year and there is a 5-year early cancellation notification period available under the contract. The Company is investigating different avenues to potentially reduce the impact of this contract on its future cash outflows.

 

<< Previous
Bullboard Posts
Next >>